Inadequate management of opioid-induced constipation in European cancer pain patients: results of a real-world, multicentre, observational study ("E-StOIC").


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
05 Oct 2024
Historique:
received: 16 06 2024
accepted: 23 09 2024
medline: 5 10 2024
pubmed: 5 10 2024
entrez: 4 10 2024
Statut: epublish

Résumé

The objectives of the study were to determine the prevalence of (uncontrolled) OIC, relevant medications / interventions employed by healthcare professionals, and the additional strategies utilised by patients, amongst European patients with cancer pain. This study was a prospective observational study conducted at 24 research sites in ten European countries. Cancer patients receiving opioid analgesics for at least a week were recruited, and asked to complete a questionnaire including background information, single question (Are you constipated?), Rome IV diagnostic criteria for OIC, Bowel Function Index (BFI), and Patient Assessment of Constipation Quality of Life questionnaire (PAC-QOL). Participants were characterised as having / not having OIC on the basis of the Rome IV diagnostic criteria. 1200 participants completed the study. 59.5% met the Rome IV diagnostic criteria for OIC: only 61.5% that met these criteria self-reported constipation. 72% participants were prescribed a regular conventional laxative / peripherally acting mu-opioid receptor antagonist (PAMORA). However, only 66% took their prescribed laxatives every day. Many participants had utilised other strategies / interventions to manage their OIC. Furthermore, 27% had needed to use suppositories, 26.5% had needed to use an enema, and 8% had had a manual evacuation. The use of PAMORAs, and other novel effective medications, was relatively uncommon. The results of this study suggest that management in Europe is often inadequate, and this undoubtedly relates to a combination of inadequate assessment, inappropriate treatment, and inadequate reassessment.

Identifiants

pubmed: 39367106
doi: 10.1007/s00520-024-08898-1
pii: 10.1007/s00520-024-08898-1
doi:

Substances chimiques

Analgesics, Opioid 0
Laxatives 0

Types de publication

Journal Article Observational Study Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

701

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Constipation LPJ, diarrhoea, (2021). In: Cherny NI, Fallon MT, Kaasa S, Portenoy RK, Currow DC (eds) Oxford Textboook of Palliative Medicine, 6th edn. Oxford University Press, Oxford, pp 545–555
Lindberg G, Hamid SS, Malfertheiner P, Thomsen O, Fernandez LB, Garisch J, Thomson A, Goh K, Tandon R, Fedail S, Wong B, Khan A, Krabshuis J, Le Mair A (2011) World Gastroenterology Organisation global guideline: Constipation: a global perspective. J Clin Gastroenterol 45:483–487. https://doi.org/10.1097/MCG.0b013e31820fb914
doi: 10.1097/MCG.0b013e31820fb914 pubmed: 21666546
Walter S, Hallbook O, Gotthard R, Bergmark M, Sjodahl R (2002) A population-based study on bowel habits in a Swedish community: prevalence of faecal incontinence and constipation. Scand J Gastroenterol 37:911–916. https://doi.org/10.1080/003655202760230865
doi: 10.1080/003655202760230865 pubmed: 12229965
Davies A, Leach C, Caponero R, Dickman A, Fuchs D, Paice J, Emmanuel A (2020) MASCC recommendations on the management of constipation in patients with advanced cancer. Support Care Cancer 28:23–33. https://doi.org/10.1007/s00520-019-05016-4
doi: 10.1007/s00520-019-05016-4 pubmed: 31396746
Camilleri M, Drossman DA, Becker G, Webster LR, Davies AN, Mawe GM (2014) Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil 26:1386–1395. https://doi.org/10.1111/nmo.12417
doi: 10.1111/nmo.12417 pubmed: 25164154 pmcid: 4358801
Drossman DA, Chang L, Chey WD, Kellow J, Tack J, Whitehead WE (2016) Rome IV functional gastrointestinal disorders: disorders of gut-brain interaction, 4
Davies A, Leach C, Butler C, Gregory A, Henshaw S, Minton O, Shorthose K, Batsari KM (2021) Opioid-induced constipation in cancer patients: a “real-world”, multicentre, observational study of diagnostic criteria and clinical features. Pain 162:309–318. https://doi.org/10.1097/j.pain.0000000000002024
doi: 10.1097/j.pain.0000000000002024 pubmed: 32701649
Crockett SD, Greer KB, Heidelbaugh JJ, Falck-Ytter Y, Hanson BJ, Sultan S (2019) American Gastroenterological Association Institute guideline on the medical management of opioid-induced constipation. Gastroenterology 156:218–226. https://doi.org/10.1053/j.gastro.2018.07.016
doi: 10.1053/j.gastro.2018.07.016 pubmed: 30340754
Dhingra L, Shuk E, Grossman B, Strada A, Wald E, Portenoy A, Knotkova H, Rl P (2013) A qualitative study to explore psychological distress and illness burden associated with opioid-induced constipation in cancer patients with advanced disease. Palliat Med 27:447–456. https://doi.org/10.1177/0269216312450358
doi: 10.1177/0269216312450358 pubmed: 22707180
Friedrichsen M, Erichsen E (2004) The lived experience of constipation in cancer patients in palliative hospital-based home care. Int J Palliat Nurs 10:321–325. https://doi.org/10.12968/ijpn.2004.10.7.14570
Søndergaard J, Christensen HN, Ibsen R, Jarbøl DE, Kjellberg J (2017) Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: a nationwide register-based cohort study in Denmark. Scand J Pain 15:83–90. https://doi.org/10.1016/j.sjpain.2017.01.006
doi: 10.1016/j.sjpain.2017.01.006 pubmed: 28850356
Fine PG, Chen YW, Wittbrodt E, Datto C (2019) Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Support Care Cancer 27:687–696. https://doi.org/10.1007/s00520-018-4366-z
doi: 10.1007/s00520-018-4366-z pubmed: 30056531
Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI; ESMO Guidelines Committee (2018) Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 29(Suppl 4):iv166-iv191. https://doi.org/10.1093/annonc/mdy152
Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, Greenlee H, Hansen E, Kamal AH, Kamdar MM, LeGrand S, Mackey S, McDowell MR, Moryl N, Nabell LM, Nesbit S, BCPS; O’Connor N, Rabow MW, Rickerson E, Shatsky R, Sindt J, Urba SG, Youngwerth JM, Hammond LJ, Gurski LA, (2019) Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17:977–1007. https://doi.org/10.6004/jnccn.2019.0038
doi: 10.6004/jnccn.2019.0038 pubmed: 31390582
Skollerud LM, Fredheim OM, Svendsen K, Skurtveit S, Borchgrevink PC (2013) Laxative prescriptions to cancer outpatients receiving opioids: a study from the Norwegian prescription database. Support Care Cancer 21:67–73. https://doi.org/10.1007/s00520-012-1494-8
doi: 10.1007/s00520-012-1494-8 pubmed: 22653367
Noguera A, Centeno C, Librada S, Nabal M (2010) Clinical use of oral laxatives in palliative care services in Spain. Support Care Cancer 18:1491–1494.  https://doi.org/10.1007/s00520-010-0956-0
Rojas-Concha L, Hansen MB, Adsersen M, Petersen MA, Groenvold M (2023) Implementation of clinical guidelines in specialized palliative care-results from a national improvement project: A national register-based study. Palliat Med 37:749–759. https://doi.org/10.1177/02692163231155977
doi: 10.1177/02692163231155977 pubmed: 36872567
Zeppetella G (1999) How do terminally ill patients at home take their medication? Palliat Med 13:469–475. https://doi.org/10.1191/026921699675653923
doi: 10.1191/026921699675653923 pubmed: 10715753
Clark K, Rowett D, Robinson M, Currow DC (2013) Uptake of methylnaltrexone in Australian patients with opioid-induced constipation: a review of the number of prescriptions presented in the first 12 months of subsidisation. BMJ Support Palliat Care 3:98–102. https://doi.org/10.1136/bmjspcare-2012-000284
doi: 10.1136/bmjspcare-2012-000284 pubmed: 24644334
Sera L, McPherson ML (2018) Management of opioid-induced constipation in hospice patients. Am J Hosp Palliat Care 35:330–335. https://doi.org/10.1177/1049909117705379
doi: 10.1177/1049909117705379 pubmed: 28423917
Oken M, Creech R, Tormey D, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655
doi: 10.1097/00000421-198212000-00014 pubmed: 7165009
Rentz AM, Yu R, Muller-Lissner S, Leyendecker P (2009) Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12:371–383. https://doi.org/10.3111/13696990903430481
doi: 10.3111/13696990903430481 pubmed: 19912069
Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O (2005) Development and validation of the Patient Assessment of Constipation Quality of Life Questionnaire. Scand J Gastroenterol 40:540–551. https://doi.org/10.1080/00365520510012208
doi: 10.1080/00365520510012208 pubmed: 16036506
Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554. https://doi.org/10.1200/JCO.2001.19.9.2542
doi: 10.1200/JCO.2001.19.9.2542 pubmed: 11331334
Our Lady’s Hospice and Care Service website: https://olh.ie/palliative-meds-info/
Laugsand EA, Jakobsen G, Kaasa S, Klepstad P (2011) Inadequate symptom control in advanced cancer patients across Europe. Support Care Cancer 19:2005–2014. https://doi.org/10.1007/s00520-010-1051-2
doi: 10.1007/s00520-010-1051-2 pubmed: 21116653
Roeland EJ, Sera CJ, Ma JD (2020) More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer. Support Care Cancer 28:1793–1797. https://doi.org/10.1007/s00520-019-04996-7
doi: 10.1007/s00520-019-04996-7 pubmed: 31332514
Fallon MT, Hanks GW (1999) Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13:159–160. https://doi.org/10.1191/026921699677653615
doi: 10.1191/026921699677653615 pubmed: 10474699
Bennett M, Cresswell H (2003) Factors influencing constipation in advanced cancer patients: a prosepctive study of opioid dose, dantron dose and physical functionsing. Palliat Med 17:418–422. https://doi.org/10.1191/0269216303pm773oa
doi: 10.1191/0269216303pm773oa pubmed: 12882260
Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12:375–382. https://doi.org/10.1191/026921698674125048
doi: 10.1191/026921698674125048 pubmed: 9924600
Ahn JS, Lin J, Ogawa S, Yuan C, O’Brien T, Le BH, Bothwell AM, Moon H, Hadjiat Y, Ganapathi A (2017) Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review. J Pain Res 10:1963–1972. https://doi.org/10.2147/JPR.S140320
doi: 10.2147/JPR.S140320 pubmed: 28860851 pmcid: 5571859
Fumita S, Imai H, Harada T, Noriyuki T, Gamoh M, Akashi Y, Sato H, Kizawa Y, Tokoro A (2020) Patients’ self-assessment of the symptoms and impact of opioid-induced constipation: results from a prospective observational cohort study of Japanese patients with cancer. J Pain Symptom Manage 59:1043-1051.e2. https://doi.org/10.1016/j.jpainsymman.2019.11.021
doi: 10.1016/j.jpainsymman.2019.11.021 pubmed: 31805362
Larkin PJ, Cherny NI, La Carpia D, Guglielmo M, Ostgarthe C, Scotte F, Ripamonti C (2018) Diagnosis, assessment and management of constipation in advanced cancer: ESMO clinical practice guidelines. Ann Oncol 29(Suppl 4):iv94-iv108. https://doi.org/10.1093/annonc/mdy148
Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358:2332–2343. https://doi.org/10.1056/NEJMoa0707377
doi: 10.1056/NEJMoa0707377 pubmed: 18509120
Chey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370:2387–2396. https://doi.org/10.1056/NEJMoa1310246
doi: 10.1056/NEJMoa1310246 pubmed: 24896818
Brenner DM, Argoff CE, Fox SM, Bochenek W, D’Astoli P, Blakesley RE, Reasner DS, O’Dea CR, Cash BD (2020) Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. Pain 161:1027–1036. https://doi.org/10.1097/j.pain.0000000000001754
doi: 10.1097/j.pain.0000000000001754 pubmed: 32310620 pmcid: 7170446
Cryer B, Katz S, Vallejo R, Popescu A, Ueno R (2014) A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 15:1825–1834. https://doi.org/10.1111/pme.12437
doi: 10.1111/pme.12437 pubmed: 24716835
Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M (2010) Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 55:2912–2921. https://doi.org/10.1007/s10620-010-1229-y
doi: 10.1007/s10620-010-1229-y pubmed: 20428949 pmcid: 2943574
National Institute for Health and Care Excellence (2015) Naloxegol for treating opioid-induced constipation. Technology appraisal guidance: TA345. National Institute for Health and Care Excellence, Manchester
National Institute for Health and Care Excellence (2020) Naldemedine for treating opioid-induced constipation. Technology appraisal guidance: TA651. National Institute for Health and Care Excellence, Manchester
Davies A, Leach C, Butler C, Patel SD, Shorthose K, Batsari KM (2023) Opioid-induced constipation: a step-wise treatment algorithm feasibility study. BMJ Support Palliat Care 13:e446-453. https://doi.org/10.1136/bmjspcare-2020-002754
doi: 10.1136/bmjspcare-2020-002754 pubmed: 34348942
Clark K, Lam L, Currow DC, Agar M (2014) A prospective study to investigate contributory factors that lead to constipation in palliative care patients. J Pain Symptom Manage 47:e1–e4. https://doi.org/10.1016/j.jpainsymman.2014.01.005
doi: 10.1016/j.jpainsymman.2014.01.005 pubmed: 24685723

Auteurs

Andrew Davies (A)

Trinity College Dublin, University College Dublin and Our Lady's Hospice & Care Services, Dublin, D6W RY72, Ireland. andavies@tcd.ie.

Norah Fagan (N)

Trinity College Dublin, University College Dublin and Our Lady's Hospice & Care Services, Dublin, D6W RY72, Ireland.

Jesus Gonzalez-Barboteo (J)

Palliative Care Department, Institut Català d'Oncologia / Research & Knowledge on Palliative Care Group (Gricopal) / ICO/UVIC Faculty of Medicine, University of VIC/Central, Barcelona, Spain.

Cosimo Chelazzi (C)

Palliative Medicine, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Guillaume Economos (G)

Centre de Soins Palliatifs, Hopital Lyon Sud, Hospices Civils de Lyon, Lyon, France.

Frank Elsner (F)

Department of Palliative Medicine, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Charlotte Leach (C)

Royal Surrey County Hospital, Guildford, UK.

Ragnhild E Monsen (RE)

Lovisenberg Diaconal Hospital, Oslo, Norway.

Wendy H Oldenmenger (WH)

Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.

Constanze Remi (C)

Department of Palliative Medicine, Faculty of Medicine, Ludwig Maximilians University, Munich, Germany.

Marieke van den Beuken-van Everdingen (M)

Center of Expertise for Palliative Care, Maastricht University Medical Center+ (MUMC+), Maastricht, The Netherlands.

Marion Wüstefeld (M)

Department of Anesthesiology and Intensive Care / Department of Oncology, Kuopio University Hospital, Kuopio, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH